Ozempic Receives New Indications in Chronic Kidney Disease

The US Food and Drug Administration (FDA) approved semaglutide (Ozempic, Novo Nordisk) for reducing the risk for worsening kidney disease and cardiovascular death in adults with both type 2 diabetes and chronic kidney disease.  The approval is based on the phase 3b results of the international FLOW kidney outcomes trial…
Read More